Yichang HEC Changjiang Pharmaceutical Co., Ltd.

This product belongs to the propionic acid class of nonsteroidal anti-inflammatory drugs, with anti-inflammatory, analgesic and antipyretic effects. It reduces the synthesis of inflammatory mediators prostaglandins by inhibiting cyclooxygenase, so that the swelling and pain of local tissues caused by prostaglandins can be controlled. The anti-inflammatory effect of this product is stronger than that of ibuprofen, and the analgesic effect is better than that of ibuprofen, phenylbutazone and aspirin, while the gastric mucosal damage effect is lower than that of aspirin and phenylbutazone. It causes slight damage to the digestive tract and the drug effect is long-lasting. This drug has a central muscle relaxant effect.

It can promote the secretion of insulin by pancreatic beta cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic alpha cells to inhibit the secretion of glucagon, inhibit the decomposition of liver glycogen, promote muscle utilization and consumption of glucose.

Extract from the above information

This product is a benzofuran derivative and a uricosuric drug. Its mechanism of action is mainly to inhibit the reabsorption of uric acid by the renal tubules, thereby reducing the concentration of uric acid in the blood.

This product is a mucolytic agent, which can inhibit the excessive formation of goblet cells that secrete mucous sputum in the trachea, and inhibit the production of high-viscosity fucoxomucin, thereby reducing the viscosity of sputum and making it easier to cough up. This product can also increase serous tracheal secretion and inhibit tracheal inflammation.